Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Tucatinib|DRUG: Doxil
Sponsor: SCRI Development Innovations, LLC
Collaborators: Seagen Inc.